UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther
  
Qalsody, an orphan medicine, is expected to be suitable for just 60 patients with ALS in the UK (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approval Standards

More from United Kingdom